Adicet.png
Adicet Bio Announces Formation of Scientific Advisory Board
July 15, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif and BOSTON, July 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer...
Adicet.png
Adicet Bio Added to the Russell 2000® Index
June 28, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif. and BOSTON, June 28, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet.png
Adicet Bio to Participate in Upcoming Investor Conferences
May 18, 2021 16:10 ET | Adicet Bio
MENLO PARK, Calif., May 18, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other...
Adicet.png
Adicet Reports First Quarter 2021 Financial Results and Provides Business Updates
May 17, 2021 07:01 ET | Adicet Bio
Initiated Phase 1 Trial of ADI-001 for the Treatment of B Cell Non-Hodgkin's Lymphoma (NHL), interim clinical data expected in late 2021 Successfully raised $143.8 million in net proceeds through a...
Adicet.png
Adicet Bio to Participate in Fireside Chat at the 7th Annual Truist Securities Life Sciences Summit
April 29, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet.png
Adicet Bio to Participate in the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
April 15, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet.png
Adicet Bio Appoints Dr. Blake Aftab as Vice President of Research
April 13, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet.png
Adicet Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 11, 2021 16:10 ET | Adicet Bio
Received IND clearance and initiated first-in-human Phase 1 clinical trial for lead asset, ADI-001, an anti-CD20 allogeneic CAR gamma-delta T cell therapy, interim clinical data expected in...
Adicet.png
Adicet Bio Appoints Dr. Andrew Sinclair to its Board of Directors
March 04, 2021 16:01 ET | Adicet Bio
MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet.png
Adicet Bio, Inc. Announces Closing of $152 Million Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
February 16, 2021 07:00 ET | Adicet Bio
MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell...